Ebola virus (EBOV) causes severe febrile illness that frequently leads to death within 10 days of infection due to multiorgan failure. Different therapeutic strategies have been developed against EBOV ...

Ebola (EBOV) and Marburg virus (MARV) are highly lethal viruses that cause severe disease in infected patients by extensively damaging the body. This includes the gastrointestinal tract. Severe ...

This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

Researchers at the University of Iowa (UI) Health Care and colleagues at the Texas Biomedical Research Institute, and Boston University, used human skin explants to track the cellular route that the ...

In the new study, the team showed that EBOV infected several different cell types in the skin explant, including macrophages, endothelial cells, fibroblasts, and keratinocytes. While some of these ...

The Journal of Infectious Diseases, Vol. 218, Supplement 5: Marburg and Ebola Viruses: Marking 50 Years Since Discovery (15 December 2018), pp. S453-S457 (5 pages) The mouse model for Ebola virus ...

Background Heterologous immunity is the induction of an immune response to an unrelated pathogen upon exposure to a different pathogen, involving memory T cells and B cells response. Studies showed ...

aLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA bRocky Mountain Veterinary Branch, ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Ebola viruses (EBOVs) assemble into ...

Los Gatos, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies ...